Key Highlights
- ARAY shares jumped 39.38% to $0.30 at Monday's close on September 28, 2026, while the Russell 2000 slipped 0.69%.
- Accuray is an established maker of radiation-oncology and radiosurgery systems that treat cancer with precisely targeted radiation.
- Companies of this kind typically trade at prices well above the sub-dollar level quoted for Accuray.
- The quoted price sits unusually far below the company's historical trading range, which is unusual for an established platform maker.
Shares of Accuray (NASDAQ:ARAY), a penny stock, ended Monday, September 28, 2026 higher by 39.38%, at $0.30. The company is an established maker of radiation-oncology and radiosurgery systems used to treat cancer with targeted radiation.
Latest Developments
ARAY shares surged at Monday's close in a session when the major indexes fell.
Accuray is an established maker of radiation-oncology and radiosurgery systems, best known for platforms that treat cancer with precisely targeted radiation.
Financial and Business Position
Companies of this kind typically trade at prices well above the sub-dollar level shown for Accuray, so the quoted price is unusually low relative to its historical range.
Medical-device names were not at the center of any of those themes, and nothing in the macro picture points to a reason for a healthcare-equipment maker to move sharply in isolation.
Stock-Market Context
Equity benchmarks in the US finished lower on Monday, September 28: the S&P 500 by 0.77% to 7,683.69, the Dow by 0.67% to 51,481.51 and the Nasdaq Composite by 0.92% to 26,820.38.
Renewed US-Iran tensions after a rejected Iranian proposal lifted oil prices, with WTI crude touching roughly $96 a barrel intraday. The 10-year Treasury Yield climbed above 5.2%, its highest level since 2007.
Such discrepancies between a quoted price and a stock's historical range are worth confirming against exchange data.
A Radiation Oncology Name at an Unusual Price
Accuray closed Monday sharply higher in a session when the major indexes fell. The quoted price sits well below the company's historical trading range, an unusual feature for an established radiation-oncology platform maker.






Please wait processing your request...